suggest that the cardioprotective effects of statins can be at Angiogenesis is another aspect of vascular function that least partially explained by the regulation of endothelial may be regulated by statin action, and Kureishi et al. [25] nitric oxide synthase (ecNOS) expression and that these has demonstrated that simvastatin stimulated phosphorylaeffects are independent of lipid-lowering actions [13] .
tion and activation of the protein kinase Akd, which Wassmann et al. [14] showed that a 30 day treatment with mediates the angiogenic activity of VEGF and NO. This atorvastatin in normocholesterolemic, spontaneously hyability holds great promise for the use of statins to treat pertensive rats improved endothelial function as assessed ischemic damage. by effects on vasorelaxation and vasoconstriction. Reactive A significant new area of vascular function that has been oxygen species decreased 62% from controls, along with a shown to be affected by statins is that of immunomodula-138% increase in ecNOS mRNA and a 209% increase in tion. Statins were shown to decrease induction of major vessel wall ecNOS activity. mRNA for aortic angiotensin histocompatibility class II (MHCII) antigen expression by type I receptor and the NADPH oxidase subunit p22phox primary macrophages and endothelial cells in response to also were significantly reduced compared to controls. interferon gamma; however, constitutive expression of Increases in inducible nitric oxide synthase (iNOS) expres-MHCII antigens was not affected [26] . This effect was due sion in cardiac myocytes also have been shown to occur to inhibition of the inducible promoter IV of the transacwith statin treatment [15] . These effects were reversible tivator CIITA. with exogenous mevalonate or geranylgeranyl-pyrophosphate, and were attributed to inhibition of Rho.
Statins also show effects on reduced inflammation and 3. Regulation of LOX-1 receptor by statins adhesion to the endothelium. Yoshida et al. [16] has recently shown that cerivastatin reduced monocyte adhePerhaps not surprisingly, statins affect other pathways sion to vascular endothelium under physiological flow related to the prevention of vascular disease. The work by conditions by decreasing expression of integrins and actin Li and coworkers on the LOX-1 receptor demonstrates polymerization via RhoA inactivation. Inoue et al. [17] effects of statins that may affect multiple pathways inshowed that four different statins decreased mRNA and dependent of lipid-lowering effects [11] . LOX-1 is a protein for IL-1b, 1L-6, and cyclooxygenase-2. These lectin-like receptor on endothelial cells that facilitates statins also induced peroxisome proliferator-activated reuptake of oxidized-LDL (ox-LDL) [27] . Increased expresceptor alpha (PPARalpha) and PPARgamma mRNA and sion of LOX-1 promotes pathobiological effects of oxprotein expression in HUVEC and hepatocytes. In addi-LDL such as increased apoptosis, suppression of constitution, expression of p22phox and p47phox, subunits of tive nitric oxide synthase (cNOS) activity and increased NADPH oxidase, were decreased by treatment with statins, cell adhesion [28] . Protein kinase B (PKB), a homologue and this effect was reversed by mevalonate, geranylgeranof v-Akt, has been shown to be important for the expresiol, farnesol, and cholesterol. Clinical studies have shown sion of cNOS activity. Since ox-LDL decreases cNOS that pravastatin significantly decreases plasma concentraexpression, changes in PKB activity may be involved in tions of C-reactive protein [18, 19] , and similar results have this effect of ox-LDL. Previous work suggested that statins been found using simvastatin and atorvastatin [20] . Statins may affect an increase in PKB activity [25] , thus it is are increasingly being employed to counteract inflammalikely they are involved in regulation of LOX-1 exprestory responses in transplantation, and pravastatin has been sion. The current work of Li et al. [11] shows that in shown to decrease plasma markers of inflammation and human coronary artery endothelial cells ox-LDL upreguimprove endothelial cell function in human heart transplant lated expression of LOX-1 protein and mRNA, which recipients [21] . In a recent, significant study Sparrow et al.
enhanced ox-LDL uptake, and at the same time decreased [22] utilized a murine model to confirm that simvastatin phosphorylation (activity) of PKB without affecting PKB directly inhibits acute and chronic inflammatory conditions protein levels. Simvastatin or atorvastatin, in a concenand shows antiatherosclerotic activity independent of its tration dependent manner, decreased the ox-LDL-mediated cholesterol lowering effect.
increase in LOX-1 expression, which resulted in less oxStatins also may reduce the incidence of vascular LDL uptake. These statins by themselves had no effect on disease by minimizing thrombogenic events. Simvastatin LOX-1 expression. Statins also increased activity of PKB has been shown to depress blood clotting by inhibiting in the presence of ox-LDL, but this effect was reversed activation of prothrombin and factor XIII, reducing rates of when cells were treated with an upstream (PI 3-kinase) factor Va generation, and by enhancing factor Va inactivainhibitor of PKB. Since the PKB pathway is involved in tion [23] . These effects were unrelated to lipid lowering other areas related to vascular disease, such as inflammaeffects. Pravastatin therapy was shown to cause a reduction tion, effects of statins on PKB could provide a common in thrombogenicity in hyperlipidemic patients due to tissue mechanism and at least partially explain these effects. plasminogen activator-and plasminogen activator
One criticism of much of the work to date on secondary inhibitor-1-mediated effects [24] . Interestingly, these fibeffects of statins is that it has been done using in vitro rinolytic / antithrombotic actions were determined not to be models. Many findings await confirmation in animal proportional to the magnitude of LDL-C reduction. models, and ultimately these mechanisms of statin action 
